VANCOUVER, BRITISH COLUMBIA--(Marketwire - August 12, 2008) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that Dr. Andrew Zhu has joined the Company’s Oncology Clinical Advisory Board. Comprised of leading oncologists, the Advisory Board plays an important role in guiding the CTCE-9908 clinical development program.
